<DOC>
	<DOCNO>NCT00803595</DOCNO>
	<brief_summary>The primary objective study confirm efficacy CS-8958 administer single inhale low dose single inhale high dose show non-inferiority oseltamivir phosphate use time alleviation influenza illness . For safety evaluation , between-group comparison make regard incidence adverse event safety measure . In secondary objective , optimum dosage CS-8958 indication evaluate base efficacy safety single inhale low high dose .</brief_summary>
	<brief_title>A Multinational Phase III Study CS-8958 ( MARVEL )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Clinical diagnosis influenza Axillary temperature &gt; = 37.5 degree C Infection bacteria specie and/or virus influenza virus Chronic respiratory disease Renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Neuraminidase inhibitor</keyword>
</DOC>